Chinese General Practice ›› 2024, Vol. 27 ›› Issue (06): 692-698.DOI: 10.12114/j.issn.1007-9572.2023.0263
• Original Research • Previous Articles Next Articles
Received:
2023-02-01
Revised:
2023-06-10
Published:
2024-02-20
Online:
2023-11-21
Contact:
CHENG Genyang
通讯作者:
程根阳
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0263
组别 | 例数 | 性别(男/女) | 年龄(岁) | 血红蛋白(g/L) | 血白蛋白[M(P25,P75),g/L] | 血尿酸(μmol/L) | 血肌酐[M(P25,P75),μmol/L] | eGFR[M(P25,P75),mL·min-1·(1.73 m2)-1] |
---|---|---|---|---|---|---|---|---|
激素治疗组 | 97 | 43/54 | 38.5±13.0 | 123.82±19.93 | 34.29(29.75,39.50) | 349.40±99.40 | 111.62(70.00,133.00) | 97.46(49.16,100.57) |
支持治疗组 | 97 | 50/47 | 37.9±11.3 | 123.03±20.95 | 36.42(32.70,41.45) | 358.79±101.47 | 131.79(72.00,173.50) | 75.17(39.16,110.84) |
检验统计量值 | 1.012a | -0.360b | 0.269b | -1.688 | -1.292b | -1.499 | -0.286 | |
P值 | 0.314 | 0.719 | 0.788 | 0.091 | 0.198 | 0.134 | 0.775 | |
组别 | 24 h尿蛋白定量[M(P25,P75),g/24 h] | 收缩压[M(P25,P75),mmHg] | 舒张压[M(P25,P75),mmHg] | M1[例(%)] | E1[例(%)] | S1[例(%)] | T1~2[例(%)] | C1~2[例(%)] |
激素治疗组 | 3.17(1.61,3.97) | 135(124,143) | 86(75,94) | 27(27.8) | 32(33.0) | 68(70.1) | 44(45.4) | 46(47.4) |
支持治疗组 | 2.74(1.33,3.45) | 137(125,146) | 89(80,95) | 17(17.5) | 22(22.7) | 70(72.2) | 46(47.4) | 41(42.3) |
检验统计量值 | -1.904 | -0.623 | -1.519 | 2.939a | 2.566a | 0.100a | 0.083a | 0.521a |
P值 | 0.057 | 0.533 | 0.129 | 0.086 | 0.109 | 0.751 | 0.773 | 0.470 |
Table 1 Comparison of clinical data between the two groups
组别 | 例数 | 性别(男/女) | 年龄(岁) | 血红蛋白(g/L) | 血白蛋白[M(P25,P75),g/L] | 血尿酸(μmol/L) | 血肌酐[M(P25,P75),μmol/L] | eGFR[M(P25,P75),mL·min-1·(1.73 m2)-1] |
---|---|---|---|---|---|---|---|---|
激素治疗组 | 97 | 43/54 | 38.5±13.0 | 123.82±19.93 | 34.29(29.75,39.50) | 349.40±99.40 | 111.62(70.00,133.00) | 97.46(49.16,100.57) |
支持治疗组 | 97 | 50/47 | 37.9±11.3 | 123.03±20.95 | 36.42(32.70,41.45) | 358.79±101.47 | 131.79(72.00,173.50) | 75.17(39.16,110.84) |
检验统计量值 | 1.012a | -0.360b | 0.269b | -1.688 | -1.292b | -1.499 | -0.286 | |
P值 | 0.314 | 0.719 | 0.788 | 0.091 | 0.198 | 0.134 | 0.775 | |
组别 | 24 h尿蛋白定量[M(P25,P75),g/24 h] | 收缩压[M(P25,P75),mmHg] | 舒张压[M(P25,P75),mmHg] | M1[例(%)] | E1[例(%)] | S1[例(%)] | T1~2[例(%)] | C1~2[例(%)] |
激素治疗组 | 3.17(1.61,3.97) | 135(124,143) | 86(75,94) | 27(27.8) | 32(33.0) | 68(70.1) | 44(45.4) | 46(47.4) |
支持治疗组 | 2.74(1.33,3.45) | 137(125,146) | 89(80,95) | 17(17.5) | 22(22.7) | 70(72.2) | 46(47.4) | 41(42.3) |
检验统计量值 | -1.904 | -0.623 | -1.519 | 2.939a | 2.566a | 0.100a | 0.083a | 0.521a |
P值 | 0.057 | 0.533 | 0.129 | 0.086 | 0.109 | 0.751 | 0.773 | 0.470 |
指标 | 单因素分析 | 多因素分析 | ||||
---|---|---|---|---|---|---|
HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | |
性别 | 0.599 | 0.324~1.108 | 0.102 | |||
年龄 | 0.992 | 0.968~1.017 | 0.518 | |||
高血压 | 1.829 | 0.995~3.359 | 0.052 | |||
血红蛋白 | 0.974 | 0.959~0.989 | 0.001 | 0.982 | 0.965~0.999 | 0.043 |
血白蛋白 | 1.000 | 0.967~1.033 | 0.990 | |||
血尿酸 | 1.005 | 1.002~1.008 | <0.001 | 1.002 | 0.999~1.006 | 0.223 |
血肌酐 | 1.016 | 1.012~1.019 | <0.001 | 1.019 | 1.012~1.026 | <0.001 |
eGFR | 0.973 | 0.962~0.985 | <0.001 | 1.020 | 1.002~1.038 | 0.031 |
24 h尿蛋白定量 | 1.165 | 1.043~1.300 | 0.007 | 1.205 | 1.053~1.378 | 0.007 |
尿红细胞计数 | 1.000 | 1.000~1.001 | 0.611 | |||
M1 | 1.108 | 0.544~2.254 | 0.778 | |||
E1 | 0.835 | 0.419~1.665 | 0.609 | |||
S1 | 1.248 | 0.628~2.482 | 0.527 | |||
T1~2 | 4.236 | 2.129~8.427 | <0.001 | 2.095 | 0.879~4.990 | 0.095 |
C1~2 | 0.856 | 0.465~1.575 | 0.617 | |||
应用激素 | 0.493 | 0.250~0.970 | 0.041 | 0.569 | 0.266~1.214 | 0.145 |
Table 2 Cox regression analysis of influencing factors of primary endpoint event in IgAN patients with high risk of CKD progression
指标 | 单因素分析 | 多因素分析 | ||||
---|---|---|---|---|---|---|
HR值 | 95%CI | P值 | HR值 | 95%CI | P值 | |
性别 | 0.599 | 0.324~1.108 | 0.102 | |||
年龄 | 0.992 | 0.968~1.017 | 0.518 | |||
高血压 | 1.829 | 0.995~3.359 | 0.052 | |||
血红蛋白 | 0.974 | 0.959~0.989 | 0.001 | 0.982 | 0.965~0.999 | 0.043 |
血白蛋白 | 1.000 | 0.967~1.033 | 0.990 | |||
血尿酸 | 1.005 | 1.002~1.008 | <0.001 | 1.002 | 0.999~1.006 | 0.223 |
血肌酐 | 1.016 | 1.012~1.019 | <0.001 | 1.019 | 1.012~1.026 | <0.001 |
eGFR | 0.973 | 0.962~0.985 | <0.001 | 1.020 | 1.002~1.038 | 0.031 |
24 h尿蛋白定量 | 1.165 | 1.043~1.300 | 0.007 | 1.205 | 1.053~1.378 | 0.007 |
尿红细胞计数 | 1.000 | 1.000~1.001 | 0.611 | |||
M1 | 1.108 | 0.544~2.254 | 0.778 | |||
E1 | 0.835 | 0.419~1.665 | 0.609 | |||
S1 | 1.248 | 0.628~2.482 | 0.527 | |||
T1~2 | 4.236 | 2.129~8.427 | <0.001 | 2.095 | 0.879~4.990 | 0.095 |
C1~2 | 0.856 | 0.465~1.575 | 0.617 | |||
应用激素 | 0.493 | 0.250~0.970 | 0.041 | 0.569 | 0.266~1.214 | 0.145 |
组别 | 例数 | 感染 | 消化道症状 | 其他不良反应 |
---|---|---|---|---|
激素治疗组 | 97 | 22(22.7) | 8(8.2) | 8(8.2) |
支持治疗组 | 97 | 10(10.3) | 2(2.1) | 6(6.2) |
χ2值 | 5.389 | 3.796 | 0.308 | |
P值 | 0.02 | 0.051 | 0.579 |
Table 3 Comparison of incidence of adverse reactions between the two groups
组别 | 例数 | 感染 | 消化道症状 | 其他不良反应 |
---|---|---|---|---|
激素治疗组 | 97 | 22(22.7) | 8(8.2) | 8(8.2) |
支持治疗组 | 97 | 10(10.3) | 2(2.1) | 6(6.2) |
χ2值 | 5.389 | 3.796 | 0.308 | |
P值 | 0.02 | 0.051 | 0.579 |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[1] | WANG Xueting, JIANG Yi. Disease Burden of Chronic Obstructive Pulmonary Disease in the BRICS Countries from 1990 to 2019 [J]. Chinese General Practice, 2024, 27(09): 1118-1125. |
[2] | HAN Junjie, WU Di, CHEN Zhisheng, XIAO Yang, SEN Gan. A Nomogram Prediction Model and Validation Study on the Risk of Complicated Diabetic Nephropathy in Type 2 Diabetes Patients [J]. Chinese General Practice, 2024, 27(09): 1054-1061. |
[3] | WANG Kai, XU Baichao, WANG Zhaoxin, SU Jianjiao. Effects of Combined Motion Intervention on Body Composition, Cardiovascular Risk Factors and Cardiopulmonary Fitness of Obese Female Adolescents [J]. Chinese General Practice, 2024, 27(09): 1109-1117. |
[4] | YUAN Yuan, ZHANG Yarong, LI Zhengang, ZHANG Li. Risk Factors of Prone Position Ventilation-related Facial Pressure Injuries and the Selection of Best Modeling Method [J]. Chinese General Practice, 2024, 27(08): 948-954. |
[5] | WU Shuqin, WANG Yuanhan, ZHENG Kaiyuan, HAN Hongjuan, KANG Jinxiu, YU Hongmei. Prognosis and Influencing Factors of Patients with Malignant Melanoma [J]. Chinese General Practice, 2024, 27(08): 942-947. |
[6] | ZHAO Fengyi, LI Xin, ZHAN Xiaokai, ZHANG Jiajia, SHEN Man, TANG Ran, FAN Sibin, HUANG Zhongxia. Survival and Prognosis Analysis of Bortezomib Based Regimen in Newly Diagnosed Super-aged Multiple Myeloma Patients [J]. Chinese General Practice, 2024, 27(08): 971-977. |
[7] | ZHENG Kui, LIU Lu, WANG Yongli, LI Hui, WANG Xuan, LI Bo, HAO Jingxia, ZHANG Yingqian. Genetic Etiology and Risk Factors for Mortality in Primary Dilated Cardiomyopathy in Children [J]. Chinese General Practice, 2024, 27(06): 679-684. |
[8] | CHEN Qianqian, RUI Fajuan, NI Wenjing, LI Jie. Research Progress in Epidemiology and Risk Factors of Primary Liver Cancer [J]. Chinese General Practice, 2024, 27(06): 637-642. |
[9] | PENG Lei, ZHU Kexiang. Research Progress of Sarcopenic Obesity in Cancer [J]. Chinese General Practice, 2024, 27(06): 643-649. |
[10] | DONG Wendi, YANG Jiani, ZHU Jie, QUAN Yujie, ZHANG Jinjing, LIU Yan, ZHANG Hairong. Study of Factors Associated with Concomitant Gastrointestinal Bleeding in Patients with Portal Vein Thrombosis in Liver Cirrhosis [J]. Chinese General Practice, 2024, 27(05): 552-556. |
[11] | FAN Caixia, LI Jiao, WEI Yanjin, GUO Dequn, LIU Cunfei, LI Zhengrong, QIU Shi. Influencing Factors of Overanticoagulation at Initial Stage of Warfarin Anticoagulation Therapy in Patients with Atrial Fibrillation [J]. Chinese General Practice, 2024, 27(03): 308-314. |
[12] | LIN Xiaomei, ZUMURETI Abudukiyimu, MA Chunhui, XU Mengge, MA Juxing, LI Xia. Study on the Correlation of Serum Interleukin-6 and Fasting Blood Glucose with Coronary Heart Disease and Adverse Cardiovascular Events [J]. Chinese General Practice, 2024, 27(03): 286-292. |
[13] | YANG Mukun, JIA Xiaoxiang, REN Zhenghong, GU Bei, BAI Wenpei. Menopause or Chronologic Aging? A Prospective Cohort Study on Risk Factors for Coronary Heart Disease in Middle-aged Women [J]. Chinese General Practice, 2024, 27(03): 280-285. |
[14] | YANG Ji, ZHANG Yao, MA Teng, TIAN Xintong, ZHAO Yingqiang. Epidemic Status, Disease Burden and Prediction of Cardiovascular Diseases in China, 1990-2019 [J]. Chinese General Practice, 2024, 27(02): 233-244. |
[15] | HE Youkuan, CAO Yong, LIN Fei, OU Yuanyuan, LI Kewen, DENG Li. Platelet Changes during Extracorporeal Membrane Oxygenation in Patients with Different Modes of Support: a Retrospective Cohort Study [J]. Chinese General Practice, 2024, 27(02): 163-167. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||